InPharm (01/17/12) Adams, Ben
Lundbeck has launched its antipsychotic drug Sycrest in the U.K. to treat acute attacks of bipolar I disorder. Sycrest (asenapine) is now available as a sublingual (quick release) treatment for patients in the UK to treat moderate to severe manic episodes in adults with bipolar I disorder. The drug is sold by Merck in the United States under the brand name Saphris. The drug has been pitted against Lilly’s Zyprexa (olanzapine) in Phase III trials, which is licensed to treat the disorder over a longer period of time, but can also be used to treat manic episodes.

Read the complete article